GNI Group Ltd
3G6
Company Profile
Business description
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
Contact
Shinjuku Park Tower
3-7-1 Nishi-Shinjuku
Shinjuku-ku
Tokyo163-1030
JPNT: +81 353263097
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
896
Stocks News & Analysis
stocks
Market too pessimistic about unloved ASX health care share
Our analysts believe a long-term margin recovery is underway.
stocks
Two overvalued ASX shares to avoid
Both shares trade at a significant premium to our fair value.
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,899.30 | 6.50 | -0.07% |
| CAC 40 | 7,959.67 | 21.40 | -0.27% |
| DAX 40 | 23,464.63 | 225.45 | 0.97% |
| Dow JONES (US) | 47,112.45 | 867.04 | 1.87% |
| FTSE 100 | 9,548.03 | 8.32 | 0.09% |
| HKSE | 25,937.63 | 43.08 | 0.17% |
| NASDAQ | 23,025.59 | 752.51 | 3.38% |
| Nikkei 225 | 49,559.07 | 899.55 | 1.85% |
| NZX 50 Index | 13,562.01 | 81.58 | 0.61% |
| S&P 500 | 6,765.88 | 60.76 | 0.91% |
| S&P/ASX 200 | 8,606.50 | 9.50 | -0.11% |
| SSE Composite Index | 3,864.18 | 5.84 | -0.15% |